Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GE Aerospace (GE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

GE AerospaceTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

GE Aerospace vs State Street SPDR S&P Biotech ETF — how do they compare? GE Aerospace trades at $364.91 (market cap $381.89B), while State Street SPDR S&P Biotech ETF trades at $159.23. The key difference: GE Aerospace pays a 0.51% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.

GEXBI
Market Cap
$381.89B
Sector
IndustrialsBroad Market / Factor
52-Week High
$381.22$164.28
52-Week Low
$265.93$86.92
Enterprise Value
$391.70B
Dividend Yield
0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GE Aerospace

GE Aerospace trades at $366.70, down 0.91% with bullish technical momentum and strong fundamental performance. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $2.02 exceeding expectations of $1.86. Revenue growth accelerated to $45.86 billion in 2025 with net income margin improving to 17.72%. Analyst consensus remains strongly positive with 24 buy ratings and a $414.11 price target, representing 13% upside potential.

The outlook remains favorable with strong aerospace demand, defense contract wins, and expanding order backlog driving growth. Key risks include elevated valuation multiples (P/E 43.4, P/S 7.68) and potential execution challenges amid heavy investment in MRO and manufacturing expansion. The company's improving cash flow generation and strategic positioning in commercial engines and defense sectors support continued upside potential.

State Street SPDR S&P Biotech ETF

XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.

The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.

Returns comparison

Trailing returns across standard periods

About GE Aerospace

General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.

Read more on GE

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI